View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 29, 2020

Fujifilm’s Phase II US trial of Avigan recruits ten out of 50 hospitalised Covid-19 patient target

By Victoria Smith

Fujifilm Toyama Chemical’s US-based Phase II trial investigating Avigan (favipiravir) in hospitalised Covid-19 patients has recruited 20% of its patient target, with the aim to close enrolment this month, a source said.

On 15 April, the company announced it expanded its manufacturing capacity for Avigan, expecting up to 100,000 treatment courses to be available by July. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU